Share

January 18, 2022; 98 (3) Editorial

Epilepsy Mortality

The Unseen and Unknown

Orrin Devinsky
First published November 18, 2021, DOI: https://doi.org/10.1212/WNL.0000000000013069
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
113

Share

Article Information

vol. 98 no. 3 93-94
DOI: 
https://doi.org/10.1212/WNL.0000000000013069
PubMed: 
34795044
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published November 18, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Orrin Devinsky, MD
  1. Orrin Devinsky, MD
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Cognitive and Behavioral Neurology; Oxford University Press, 2002 Epilepsy: Patient and Family Guide, Demos Press, 2008 Alternative Therapies for Epilepsy, Demos Press, 2012 Epilepsy In Children, Demos Press, 2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have consulted for Marinus, Ultragenyx, Xenon and ZOgenix and The Center for Discovery

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Scientific Advisory Board and/or Equity Interest for Estate biosciences, Tevard, Egg Rock, Engage, Script biosciences, Regel Biosciences, Empatica, Rettco, Receptor Life Sciences, California Cannabis Enterprises, SilverSpike and Tilray. Principal Investigator, North American SUDEP Registry and Sudden Unexplained Childhood Death Registry and Research Collaborative Funded by NINDS, NIMH, Dept of Defense, CDC

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. For research support: GW Pharmaceuticals Novartis Marinus Eisai Zogenix Ovid Pharma Silver Spike Epilepsy Foundation Script Therapeutics Regel Therapeutics

    Research Support, Government Entities:

    1. Ongoing Support NIH R01 R01MH111417 (PI: N Petridou) 9/22/2016 – 6/30/2021 Development and validation of empirical models of the neuronal population activity underlying non-invasive human brain measurements The aims of this project are 1) Characterize, model and quantify the exact electrophysiological response of neuronal populations to external stimulation, 2) Characterize, model and quantify the exact haemodynamic response in single voxels to external stimulation, 3) Build comprehensive and integrative models linking stimuli to a) neuronal population electrophysiological activity and b) haemodynamic signals, in order to accurately relate haemodynamics measures to neuronal population activity. Role: Co-Investigator NIH 1RF1MH116978 (PI: E Yacoub) 9/1/2018 – 8/30/2022 Neural and vascular underpinnings of laminar fMRI in humans The three aims to this project are 1) validate laminar fMRI against laminar electrophysiology in humans to create a neurovascular coupling model using an oddball paradigm, 2) generalize the neurovascular coupling model to a novel, cross-modal associative learning task, 3) generalize the laminar-fMRI model developed in Aim 1 and 2 to networks of brain regions and validate the results against intracranial electrophysiological signals measured in human subjects in an audio/visual associative learning task. NIH U24NS113847 (PI: L Doan) 7/1/2019 – 6/30/2024 EPPIC-NET The Data Coordinating Center (DCC) of the EPPIC-Net, in close collaboration with the network’s Clinical Coordinating Center (CCC), the Specialized Clinical Centers (SCCs), HEAL, and government partners, will provide statistical and data management expertise for conducting high-quality efficient studies for developing non-addictive treatments for pain. In addition, it will compile a collection of clinical and biomarker data and establish a repository for biospecimens. These resources will be linked and shared with the community of pain researchers.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Rettco - Stock Tevard - Stock Engage - Stock Qstate - Stock Tilray - Stock Options Leafly - Stock Docklight - Stock Left coast ventures - Stock California Cannabis Enterprises - stock Receptor Life Sciences - Stock Egg Rock - Stock Empatica - Stock SilverSpike - Stock Regel Biosciences - stock Script biosciences - Stock

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, New York University Grossman School of Medicine, New York City.
  1. Correspondence
    Dr. Devinsky od4{at}nyu.edu
View Full Text

Article usage

Article usage: November 2021 to May 2022

AbstractFullPdfSource
Nov 20210040Highwire
Dec 20210013Highwire
Jan 20226137839Highwire
Feb 202218777Highwire
Mar 202214724Highwire
Apr 20227763Highwire
May 202210037Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me